151 related articles for article (PubMed ID: 11138686)
1. How far have we come with solid (nonhematologic) tumor radioimmunotherapy?
Breitz HB
J Nucl Med; 2000 Dec; 41(12):2011-4. PubMed ID: 11138686
[No Abstract] [Full Text] [Related]
2. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
[TBL] [Abstract][Full Text] [Related]
3. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.
Visser GW; Gerretsen M; Herscheid JD; Snow GB; van Dongen G
J Nucl Med; 1993 Nov; 34(11):1953-63. PubMed ID: 8229241
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience.
Colnot DR; Quak JJ; Roos JC; de Bree R; Wilhelm AJ; Snow GB; van Dongen GA
Head Neck; 2001 Jul; 23(7):559-65. PubMed ID: 11400244
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy of cancer: arming the missiles.
Goldenberg DM; Griffiths GL
J Nucl Med; 1992 Jun; 33(6):1110-2. PubMed ID: 1597724
[No Abstract] [Full Text] [Related]
6. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
Colnot DR; Wilhelm AJ; Cloos J; Roos JC; de Bree R; Quak JJ; Snow GB; van Dongen GA
J Nucl Med; 2001 Sep; 42(9):1364-7. PubMed ID: 11535726
[TBL] [Abstract][Full Text] [Related]
7. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
[TBL] [Abstract][Full Text] [Related]
8. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals.
Ferro-Flores G; Arteaga de Murphy C
Adv Drug Deliv Rev; 2008 Sep; 60(12):1389-401. PubMed ID: 18547675
[TBL] [Abstract][Full Text] [Related]
11. Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning.
Zalutsky MR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1958-60. PubMed ID: 16609003
[No Abstract] [Full Text] [Related]
12. Monoclonal antibodies for diagnosis and therapy of squamous cell carcinoma of the head and neck.
Gripp FM; Quak J; Leverstein H; Schrijvers A; Gerretsen M; Brakenhoff R; Van Dongen G; Snow GB; Rapoport A
Sao Paulo Med J; 1994; 112(3):612-21. PubMed ID: 7638523
[No Abstract] [Full Text] [Related]
13. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M
Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Reilly RM
J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
[No Abstract] [Full Text] [Related]
15. Current status of therapy of solid tumors.
Jhanwar YS; Divgi C
J Nucl Med; 2005 Jan; 46 Suppl 1():141S-50S. PubMed ID: 15653662
[TBL] [Abstract][Full Text] [Related]
16. Clinical radioimmunotherapy.
Knox SJ; Meredith RF
Semin Radiat Oncol; 2000 Apr; 10(2):73-93. PubMed ID: 10727597
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model.
Wang SX; Bao A; Herrera SJ; Phillips WT; Goins B; Santoyo C; Miller FR; Otto RA
Clin Cancer Res; 2008 Jun; 14(12):3975-83. PubMed ID: 18559620
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy and apoptotic induction on CK19-overexpressing human cervical carcinoma cells with Re-188-mAbCx-99.
Chang CH; Tsai LC; Chen ST; Yuan CC; Hung MW; Hsieh BT; Chao PL; Tsai TH; Lee TW
Anticancer Res; 2005; 25(4):2719-28. PubMed ID: 16080517
[TBL] [Abstract][Full Text] [Related]
19. [Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha].
Mutschler J; Steinbach G; Bunjes D; Reske SN; Buchmann I
Nuklearmedizin; 2009; 48(1):30-6. PubMed ID: 19212609
[TBL] [Abstract][Full Text] [Related]
20. Addendum to: Basic immunology of antibody targeted radiotherapy: in regard to Wong (Int J Radiat Oncol Biol Phys 2006;66: S8-S14).
Allen BJ
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):314. PubMed ID: 17448888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
